The Centers for Disease Control and Prevention in the U.S. just announced an investigation of a multistate outbreak of e-cigarette, or vaping, product use associated lung injury (EVALI). By November there were over 1,800 confirmed and probable cases and 37 deaths.1 This opens the safety of Electronic nicotine delivery systems (ENDS) to scrutiny once more.
In early August 2019, the US Centers for Disease Control and Prevention (CDC) issued a Clinician Outreach and Communication Activity urging clinicians to report possible cases of unexplained vaping-associated pulmonary illness to their state/local health departments.
The potential health risks of vaping – the use of e-cigarettes to deliver nicotine or cannabinoids as a vapor instead of smoke – are now capturing headlines for an alarming spike in sickness. RGA’s Dr. Dave Rengachary, Senior Vice President and Chief Medical Director, U.S. Mortality Markets, briefly discusses what is known, and not known.
Smoking cessation has been a large contributor to improving mortality over the past few decades and tobacco use, amongst adults and teens, is at an all-time low. However, the trend of vaping and e-cigarettes has exploded. What are the implications for insurers?
Despite its dwindling popularity in many countries, smoking remains the leading preventable cause of illness and premature death in the world.
E-Cigarette use is on the up, with large tobacco companies now major players in this market. Should we be worried?
An increasingly discussed area in life insurance circles is the manner in which marijuana and e-cigarettes are addressed by life insurance carriers.
E-cigarettes, the tobacco-free devices that deliver nicotine in an aerosol vapor, appeal almost exclusively to current and recent smokers. Fewer than 1% of people who have never smoked use e-cigarettes.